Hypera Lines Up Brazilian Semaglutide Launch Next Year
As Firm Sees ‘Aggressive’ Generic Competition In Its Domestic Market
Speaking as Hypera delivered its full year-results, CEO Breno Oliveira has set out plans for the Brazilian firm to launch an Ozempic rival in its domestic market next year. Meanwhile, the company is dealing with increasingly aggressive local generic competition.
